Publication Date 01/07/2014         Volume. 6 No. 6   
Information to Pharmacists


From the desk of the editor

Welcome to the July 2014 homepage edition of i2P (Information to Pharmacists) E-Magazine.
At the commencement of 2014 i2P focused on the need for the entire profession of pharmacy and its associated industry supports to undergo a renewal and regeneration.
We are now half-way through this year and it is quite apparent that pharmacy leaders do not yet have a cohesive and clear sense of direction.
Maybe the new initiative by Woolworths to deliver clinical service through young pharmacists and nurses may sharpen their focus.
If not, community pharmacy can look forward to losing a substantial and profitable market share of the clinical services market.
Who would you blame when that happens?
But I have to admit there is some effort, even though the results are but meagre.
In this edition of i2P we focus on the need for research about community pharmacy, the lack of activity from practicing pharmacists and when some research is delivered, a disconnect appears in its interpretation and implementation.

read more
open full screen

Recent Comments

Click here to read...

Australian scientists discover key to halt nerve fibre damage in MS

Staff Researcher

articles by this author...

Editing and Researching news and stories about Australian and International Pharmacy Issues

Scientists from RMIT and Monash Universities announced today a discovery that shows blocking a specific protein may have the ability to act as ‘hand brake’ to the progression of the disease in people with Multiple Sclerosis (MS).
These findings are published today in the prestigious journal Brain from Oxford University Press. The study was led by Dr Steven Petratos from the Monash Immunology and Stem Cell Laboratories and RMIT University. The publication of this study is coincidentally at a time when Australians are asked to Kiss Goodbye to MS in many events leading up to World MS Day in May.

Dr Petratos, together with Jeremy Wright, Chief Executive of MS Research Australia, one of the organisations funding the research, will be at a press conference at 12:30 sharp at Monash University, Clayton to announce the results. NB there will be animation of the research available for TV and xxxx, a patient with MS will be present to discuss the implications of the research for those with the disease.

MS is one of the most common, chronic neurologic diseases of adults worldwide, affecting up to 20,000 Australians, with 1,000 new diagnoses made each year. MS tends to strike early in adulthood, with women three times more likely than men to be diagnosed. The total direct cost to the Australian community of MS is just over $1 billion annually.

MS is thought to be caused by the body’s own immune system mistakenly attacking the brain, spinal cord or optic nerves. The primary target of this attack is myelin, the protective coating around the nerve fibres, which carry nerve impulses between nerve cells. These attacks cause active MS lesions and the nerve cells themselves can also be damaged.

So the research team, headed by Dr Steven Petratos, has shown that a modified version of a specific protein is present within active MS lesions in a laboratory model of MS. This modified protein then interacts with another protein to cause nerve fibre damage. When the scientists blocked either the modification or the interaction between the two proteins, disease progression was halted.

‘Blocking the same protein in people with MS could provide a ‘hand brake’ to the progression of the disease’ said Professor Richard Boyd, Director of the Monash University Immunology and Stem Cell Laboratories. Dr Petratos said that the particular method used to form the block has already been approved – for the treatment of other disease conditions – by the US Food and Drug Administration and Australia’s Therapeutic Goods Administration. ‘This should mean that clinical trials – once they start – will be fast tracked as the form of administration has already been approved,’ he said.

The research was done in collaboration with scientists from the University of Toronto and Yale University in the US, with major funding from the National Multiple Sclerosis Society of the United States of America and partial funding from MS Research Australia. ‘This is a great step forward in providing better treatments for MS and hope for people with the disease,’ said Jeremy Wright, CEO of MS Research Australia, ‘We are very pleased to be involved via funding this project’.

Return to home

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

More information about formatting options

This question is for testing whether you are a genuine visitor, to prevent automated spam submissions.
Incorrect please try again
Enter the words above: Enter the numbers you hear:

Clinical Newsfeed

health news headlines provided courtesy of Medical News Today.

Click here to

If any difficulty is found in subscribing, please use the "Contact Us" panel found in the navigation bar with the message "subscribe" and your email address.

Subscribe to our mailing list

Email Format


  • Copyright (C) 2000-2015 Computachem Services, All Rights Reserved.

Website by Ablecode